The U.S. Food and Drug Administration has approved GlaxoSmithKline’s Incruse Ellipta (umeclidinium) as a treatment for patients with chronic obsessive pulmonary disease, according to a Medscape report ...
Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...
Novo weathering the storm in Russia; Mylan and Gilead expand hep C licensing pact; NICE OKs Soliris;
Report > GlaxoSmithKline ($GSK) has rolled out new respiratory treatments Arnuity Ellipta for asthma and Incruse Ellipta for COPD in the U.S. Release > Purdue Pharma has launched Hysingla ER, a ...
LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback